Gilead Tops Profit Estimates, Raises 2015 Sales Forecast

Updated on
  • Biotech's third-quarter revenue surges 37% to $8.3 billion
  • Hepatitis drug Sovaldi beats expectations, Harvoni misses

Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted third-quarter profit that topped analysts’ estimates and raised its forecast for the year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.